Keytruda is a prescription medication used to treat various types of cancer, including melanoma, lung cancer, and bladder cancer. It works by blocking a protein called PD-1, which helps the body's immune system fight cancer cells. However, Keytruda can be expensive, and some insurance companies may have restrictions on coverage.

According to Drug Patent Watch [1], Keytruda is protected by several patents that prevent generic versions from being sold until 2028. This means that the medication is only available as a brand-name drug, which can be more expensive than generic alternatives.

To help patients afford Keytruda, the manufacturer, Merck, offers financial assistance programs. The Keytruda Patient Assistance Program [2] provides eligible patients with free medication or reimbursement for out-of-pocket costs. Additionally, the Merck Access Program [3] offers support for patients who need help navigating insurance coverage and financial assistance options.

It is important to note that insurance coverage for Keytruda may vary depending on the patient's specific plan and the type of cancer being treated. Some insurance companies may require prior authorization or have restrictions on the amount of medication that can be prescribed. Patients should check with their insurance provider to determine their coverage and any potential restrictions.

In conclusion, while Keytruda is protected by patents and may be expensive, there are financial assistance programs available to help patients afford the medication. However, insurance coverage for Keytruda may vary and may have restrictions, so patients should check with their insurance provider for more information.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/financial-support/
[3] https://www.merckaccessprogram-keytruda.com/hcc/affordability.html